Novartis To Pull Valturna From U.S. Market As FDA Warns Of Risks With Aliskiren Meds

FDA warns that use of aliskiren-containing blood pressure drugs with ACE inhibitors or angiotensin receptor blockers may increase risk of kidney impairment, hypotension and hyperkalemia; Novartis to continue to sell four other aliskiren products.